Renal-type clear cell carcinoma (RTCCC) of the prostate is an extremely rare histological variant of prostate cancer, with very few reported cases in the literature. It is characterized by cells with abundant clear cytoplasm and has an aggressive clinical course. In this report, we present a rare case of RTCCC of the prostate. We describe a 60-year-old male with a two-year history of urinary frequency, urgency, and dysuria, who was admitted to the hospital for benign prostatic hyperplasia. Ultrasound and magnetic resonance imaging (MRI) revealed prostate enlargement. The patient subsequently underwent transurethral resection of the prostate. A total of 150 g of tissue was resected, demonstrating morphological and immunohistochemical similarities to clear cell carcinoma of the kidney. A whole-body FDG PET/computed tomography (CT) scan did not detect any renal masses but showed significant uptake in the prostate, along with pelvic lymph node metastasis. The patient subsequently received radiation therapy. To the best of our knowledge, reports of clear cell carcinoma of the prostate are exceedingly rare.
{"title":"Renal-type clear cell carcinoma of the prostate: a rare case report","authors":"Hongjun Xie , Jiaqi Chen , Xinqi Pei , Zhenkun Ma, Liang Liang, Zhao Yang","doi":"10.1016/j.cpccr.2025.100394","DOIUrl":"10.1016/j.cpccr.2025.100394","url":null,"abstract":"<div><div>Renal-type clear cell carcinoma (RTCCC) of the prostate is an extremely rare histological variant of prostate cancer, with very few reported cases in the literature. It is characterized by cells with abundant clear cytoplasm and has an aggressive clinical course. In this report, we present a rare case of RTCCC of the prostate. We describe a 60-year-old male with a two-year history of urinary frequency, urgency, and dysuria, who was admitted to the hospital for benign prostatic hyperplasia. Ultrasound and magnetic resonance imaging (MRI) revealed prostate enlargement. The patient subsequently underwent transurethral resection of the prostate. A total of 150 g of tissue was resected, demonstrating morphological and immunohistochemical similarities to clear cell carcinoma of the kidney. A whole-body FDG PET/computed tomography (CT) scan did not detect any renal masses but showed significant uptake in the prostate, along with pelvic lymph node metastasis. The patient subsequently received radiation therapy. To the best of our knowledge, reports of clear cell carcinoma of the prostate are exceedingly rare.</div></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":"20 ","pages":"Article 100394"},"PeriodicalIF":0.2,"publicationDate":"2025-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145222369","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Hemoglobin SS (Hb SS) disease is a genetic condition leading to acute and chronic complications in all organ systems. There is limited data on cancer treatment outcomes in this population. This case report presents a woman in her mid-40 s with Hb SS disease and early-stage triple-negative breast cancer (TNBC), treated successfully with the Keynote 522 regimen combining chemotherapy (paclitaxel, carboplatin, doxorubicin and cyclophosphamide) and pembrolizumab. Despite potential risks, the patient tolerated therapy well with no sickle cell crises and only expected moderate side effects. This case demonstrates the feasibility of aggressive cancer treatment in patients with Hb SS disease when managed with close multidisciplinary care, though more research is needed on immunotherapy safety in this group.
{"title":"Effective treatment of early triple-negative breast cancer in a patient with sickle cell disease through chemotherapy and immune checkpoint inhibitor therapy: The keynote 522 regimen","authors":"Luise Josefine Froessl, Stevany Saxon-Filipe, Siayareh Rambally, Samira Syed","doi":"10.1016/j.cpccr.2025.100393","DOIUrl":"10.1016/j.cpccr.2025.100393","url":null,"abstract":"<div><div>Hemoglobin SS (Hb SS) disease is a genetic condition leading to acute and chronic complications in all organ systems. There is limited data on cancer treatment outcomes in this population. This case report presents a woman in her mid-40 s with Hb SS disease and early-stage triple-negative breast cancer (TNBC), treated successfully with the Keynote 522 regimen combining chemotherapy (paclitaxel, carboplatin, doxorubicin and cyclophosphamide) and pembrolizumab. Despite potential risks, the patient tolerated therapy well with no sickle cell crises and only expected moderate side effects. This case demonstrates the feasibility of aggressive cancer treatment in patients with Hb SS disease when managed with close multidisciplinary care, though more research is needed on immunotherapy safety in this group.</div></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":"20 ","pages":"Article 100393"},"PeriodicalIF":0.2,"publicationDate":"2025-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145108973","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-09-14DOI: 10.1016/j.cpccr.2025.100392
Nilesh Kapoor , Malcolm Su , Rochelle Horadam , Dawn Klemow , Samira Syed
Hepatic visceral crisis is a life-threatening manifestation of disease progression in 10–20 % of patients with metastatic breast cancer. The condition is defined as a rapid rise in bilirubin > 1.5 times upper limit of normal (ULN) in the absence of biliary tract obstruction or Gilbert’s syndrome. Prompt disease control is required to prevent progression to liver failure and death. There are no standard treatment regimens for hepatic visceral crisis and the prognosis is dismal. Trastuzumab deruxtecan (T-DXd) is an antibody-drug conjugate that has recently been approved for patients with metastatic HER2-positive, HER2-low, and HER2-ultralow breast cancer after progression on prior chemotherapy or endocrine therapy. Patients with hepatic visceral crises were not included in any clinical trials for T-DXd and, therefore, no manufacturer-based guidelines on administration or dosing of T-DXd are available in this setting. In this case study, a patient with metastatic HER2-low breast cancer presented with hepatic visceral crisis after progression on two prior lines of endocrine-based therapy. Within a span of days, her total bilirubin had risen to 19 mg/dL and her AST and ALT were both > 15 times ULN. She was offered T-DXd and had rapid, dramatic improvement in her liver chemistries and in her functional status. She received the drug for 25 cycles, resulting in a durable clinical and radiographic response for one and a half years. This case study supports the use of T-DXd in hepatic visceral crisis. Further research should be done to validate its use in this life-threatening setting.
{"title":"Successful use of trastuzumab deruxtecan in hepatic visceral crisis secondary to metastatic HER2-low breast cancer","authors":"Nilesh Kapoor , Malcolm Su , Rochelle Horadam , Dawn Klemow , Samira Syed","doi":"10.1016/j.cpccr.2025.100392","DOIUrl":"10.1016/j.cpccr.2025.100392","url":null,"abstract":"<div><div>Hepatic visceral crisis is a life-threatening manifestation of disease progression in 10–20 % of patients with metastatic breast cancer. The condition is defined as a rapid rise in bilirubin > 1.5 times upper limit of normal (ULN) in the absence of biliary tract obstruction or Gilbert’s syndrome. Prompt disease control is required to prevent progression to liver failure and death. There are no standard treatment regimens for hepatic visceral crisis and the prognosis is dismal. Trastuzumab deruxtecan (T-DXd) is an antibody-drug conjugate that has recently been approved for patients with metastatic HER2-positive, HER2-low, and HER2-ultralow breast cancer after progression on prior chemotherapy or endocrine therapy. Patients with hepatic visceral crises were not included in any clinical trials for T-DXd and, therefore, no manufacturer-based guidelines on administration or dosing of T-DXd are available in this setting. In this case study, a patient with metastatic HER2-low breast cancer presented with hepatic visceral crisis after progression on two prior lines of endocrine-based therapy. Within a span of days, her total bilirubin had risen to 19 mg/dL and her AST and ALT were both > 15 times ULN. She was offered T-DXd and had rapid, dramatic improvement in her liver chemistries and in her functional status. She received the drug for 25 cycles, resulting in a durable clinical and radiographic response for one and a half years. This case study supports the use of T-DXd in hepatic visceral crisis. Further research should be done to validate its use in this life-threatening setting.</div></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":"20 ","pages":"Article 100392"},"PeriodicalIF":0.2,"publicationDate":"2025-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145108972","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-09-01DOI: 10.1016/j.cpccr.2025.100380
Caterina Porciani , Piero Colombatto , Simone Guadagni , Gabriele Ricco , Prof. Luca Morelli , Prof. Laura Caponi , Prof. Daniela Campani , Annalisa Comandatore , Giusi Desire' Sciume' , Prof. Paola Migliorini , Piero Boraschi , Prof. Maurizia Brunetto , Prof. Giulio Di Candio
{"title":"Corrigendum to “Stauffer syndrome in a tumor of the pancreatic tail: A paracrine pathogenesis, rather than an inflammatory disimmune phenomenon – a case report” [Current Problems in Cancer Case Reports (2024) 15(24):100320]","authors":"Caterina Porciani , Piero Colombatto , Simone Guadagni , Gabriele Ricco , Prof. Luca Morelli , Prof. Laura Caponi , Prof. Daniela Campani , Annalisa Comandatore , Giusi Desire' Sciume' , Prof. Paola Migliorini , Piero Boraschi , Prof. Maurizia Brunetto , Prof. Giulio Di Candio","doi":"10.1016/j.cpccr.2025.100380","DOIUrl":"10.1016/j.cpccr.2025.100380","url":null,"abstract":"","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":"19 ","pages":"Article 100380"},"PeriodicalIF":0.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145047880","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-08-29DOI: 10.1016/j.cpccr.2025.100390
Qi Yinuo (漆伊诺), Jing Luo (罗静)
Breast angiosarcoma is a rare and aggressive tumor with a generally poor prognosis. Given its lack of pathognomonic symptoms and non-specific imaging findings, diagnosis is challenging and mostly depends on pathological reports. Optimal management is still unclear and controversial. Herein reported is a case of post-menopausal primary breast angiosarcoma. A 65-year-old lady, presented with a large palpable mass in her left breast. Mammogram findings were non-specific, but Ultrasound and Magnetic Resonance Imaging (MRI) raised high suspicion of vascular origin. A core needle biopsy was taken through the mass, with the pathology report indicating breast adenosis. Then she received lumpectomy, but the microscopic examination and immunohistochemistry staining of excised tissue suggested well-differentiated angiosarcoma. Three months after her initial surgery, she underwent a further mastectomy. Taking the tumor size and histological grade into consideration, subsequent adjuvant therapy is not recommended, but the frequency of follow-up should be increased. She is still alive. Pathognomonic signs on radiological imaging, especially MRI, do help in characterizing these tumors and raising the suspicion of vascular endothelial origins of them. Ultrasound-guided biopsy is recommended to get an early diagnosis, but in some cases, due to the limited sample size, it can be mistaken for benign lesion or false negative results may be given too. This could delay the diagnosis and efficient treatment of this aggressive malignancy. We recommend that physicians pay more attention when encountering radiology-pathology incoherence and should consider the need to review the results again or obtain additional samples that have yielded more accurate pathology results.
{"title":"Misdiagnosis of primary angiosarcoma of the breast: A case report","authors":"Qi Yinuo (漆伊诺), Jing Luo (罗静)","doi":"10.1016/j.cpccr.2025.100390","DOIUrl":"10.1016/j.cpccr.2025.100390","url":null,"abstract":"<div><div>Breast angiosarcoma is a rare and aggressive tumor with a generally poor prognosis. Given its lack of pathognomonic symptoms and non-specific imaging findings, diagnosis is challenging and mostly depends on pathological reports. Optimal management is still unclear and controversial. Herein reported is a case of post-menopausal primary breast angiosarcoma. A 65-year-old lady, presented with a large palpable mass in her left breast. Mammogram findings were non-specific, but Ultrasound and Magnetic Resonance Imaging (MRI) raised high suspicion of vascular origin. A core needle biopsy was taken through the mass, with the pathology report indicating breast adenosis. Then she received lumpectomy, but the microscopic examination and immunohistochemistry staining of excised tissue suggested well-differentiated angiosarcoma. Three months after her initial surgery, she underwent a further mastectomy. Taking the tumor size and histological grade into consideration, subsequent adjuvant therapy is not recommended, but the frequency of follow-up should be increased. She is still alive. Pathognomonic signs on radiological imaging, especially MRI, do help in characterizing these tumors and raising the suspicion of vascular endothelial origins of them. Ultrasound-guided biopsy is recommended to get an early diagnosis, but in some cases, due to the limited sample size, it can be mistaken for benign lesion or false negative results may be given too. This could delay the diagnosis and efficient treatment of this aggressive malignancy. We recommend that physicians pay more attention when encountering radiology-pathology incoherence and should consider the need to review the results again or obtain additional samples that have yielded more accurate pathology results.</div></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":"20 ","pages":"Article 100390"},"PeriodicalIF":0.2,"publicationDate":"2025-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145121237","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-08-17DOI: 10.1016/j.cpccr.2025.100387
McCawley Clark-Dickson , Alireza Khani , T․Michael Hughes , Graeme Rich , Kazi Nahar
Immune checkpoint inhibitors (ICIs) are increasingly utilised in the treatment of advanced malignancies. ICIs can result in a wide array of immune-related adverse events of which gastrointestinal toxicities are common. We present a 52-year-old female with severe dysphagia and heartburn despite proton pump inhibitor therapy whilst receiving pembrolizumab for breast cancer. A diagnosis of ICI esophagitis was made following gastroscopy with esophageal specimens when combined with the patients’ symptoms and immunotherapy exposure. Pembrolizumab was discontinued and she was treated with oral viscous budesonide which has proven efficacy in eosinophilic esophagitis but is not well established in treatment of ICI-related esophagitis. There was an impressive response to oral viscous budesonide, and this avoided the need for systemic immunosuppression. This is the first case in the literature to describe the presentation, treatment protocol and outcome for a patient treated with oral viscous budesonide for ICI-related esophagitis.
{"title":"Immune checkpoint inhibitor esophagitis with excellent response to oral viscous budesonide","authors":"McCawley Clark-Dickson , Alireza Khani , T․Michael Hughes , Graeme Rich , Kazi Nahar","doi":"10.1016/j.cpccr.2025.100387","DOIUrl":"10.1016/j.cpccr.2025.100387","url":null,"abstract":"<div><div>Immune checkpoint inhibitors (ICIs) are increasingly utilised in the treatment of advanced malignancies. ICIs can result in a wide array of immune-related adverse events of which gastrointestinal toxicities are common. We present a 52-year-old female with severe dysphagia and heartburn despite proton pump inhibitor therapy whilst receiving pembrolizumab for breast cancer. A diagnosis of ICI esophagitis was made following gastroscopy with esophageal specimens when combined with the patients’ symptoms and immunotherapy exposure. Pembrolizumab was discontinued and she was treated with oral viscous budesonide which has proven efficacy in eosinophilic esophagitis but is not well established in treatment of ICI-related esophagitis. There was an impressive response to oral viscous budesonide, and this avoided the need for systemic immunosuppression. This is the first case in the literature to describe the presentation, treatment protocol and outcome for a patient treated with oral viscous budesonide for ICI-related esophagitis.</div></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":"19 ","pages":"Article 100387"},"PeriodicalIF":0.2,"publicationDate":"2025-08-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144903723","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-08-15DOI: 10.1016/j.cpccr.2025.100389
Aneeqa Zafar , Sumana Veeravelli , Kenneth Iczkowski , John Paul Graff , Paul Kaesberg , Mamta Parikh
Anemia is a common occurrence in patients with prostate cancer and has numerous associated etiologies including androgen deprivation, radiation toxicity, bone marrow infiltration from cancer, anemia of chronic inflammation, poor nutritional status and bone marrow suppression from chemotherapy. Anemia in metastatic castration resistant prostate cancer (mCRPC) has been associated with a worse prognosis. While anemia associated with solid tumors generally is attributable to either the malignancy or the treatment given for the malignancy, prostate cancer is unique in that it is an indolent disease with fewer cytotoxic treatments and primarily affecting a geriatric population, thus leading to more varied causes of anemia. Non-treatment related causes of anemia ought to be recognized to prevent further morbidity and mortality in this vulnerable patient population. We outline cases that exemplify this spectrum.
{"title":"Casting a wide net for anemia in advanced prostate cancer: A case series","authors":"Aneeqa Zafar , Sumana Veeravelli , Kenneth Iczkowski , John Paul Graff , Paul Kaesberg , Mamta Parikh","doi":"10.1016/j.cpccr.2025.100389","DOIUrl":"10.1016/j.cpccr.2025.100389","url":null,"abstract":"<div><div>Anemia is a common occurrence in patients with prostate cancer and has numerous associated etiologies including androgen deprivation, radiation toxicity, bone marrow infiltration from cancer, anemia of chronic inflammation, poor nutritional status and bone marrow suppression from chemotherapy. Anemia in metastatic castration resistant prostate cancer (mCRPC) has been associated with a worse prognosis. While anemia associated with solid tumors generally is attributable to either the malignancy or the treatment given for the malignancy, prostate cancer is unique in that it is an indolent disease with fewer cytotoxic treatments and primarily affecting a geriatric population, thus leading to more varied causes of anemia. Non-treatment related causes of anemia ought to be recognized to prevent further morbidity and mortality in this vulnerable patient population. We outline cases that exemplify this spectrum.</div></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":"19 ","pages":"Article 100389"},"PeriodicalIF":0.2,"publicationDate":"2025-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144888815","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
We describe a rare case of SDHB-variant gastric gastrointestinal stromal tumor (GIST) in a 37-year-old woman. The tumor exhibited an unusually aggressive clinical course originating from the lesser curvature of the stomach and extending through the esophageal hiatus into the thoracic cavity. Imaging revealed multiple pulmonary nodules without hepatic or lymph nodal metastases. Immunohistochemical analysis showed positivity for KIT and DOG1, and targeted sequencing identified a pathogenic SDHB R46Q variant. Surgical resection was deemed infeasible due to tumor size and location, and the patient received sequential systemic therapies including imatinib, sunitinib, regorafenib, and pimitespib. However, both primary lesion and pulmonary metastases demonstrated rapid progression, and the patient died within six months of treatment initiation. Succinate dehydrogenase (SDH)-deficient GISTs often involve hepatic and lymph node metastases but generally follow an indolent clinical course. However, this case demonstrated exclusive pulmonary metastases and rapid progression. The atypical metastatic pattern and aggressive course suggest biological heterogeneity within SDH-deficient GISTs and underscore importance of early molecular profiling and close clinical monitoring.
{"title":"Rapid SDHB-variant gastric GIST progression with thoracic extension and multiple pulmonary metastases","authors":"Shiro Matsumoto , Hironori Yamaguchi , Takehiro Kagaya , Ayumi Matsumoto , Noriyoshi Fukushima , Yoshinori Hosoya","doi":"10.1016/j.cpccr.2025.100388","DOIUrl":"10.1016/j.cpccr.2025.100388","url":null,"abstract":"<div><div>We describe a rare case of <em>SDHB</em>-variant gastric gastrointestinal stromal tumor (GIST) in a 37-year-old woman. The tumor exhibited an unusually aggressive clinical course originating from the lesser curvature of the stomach and extending through the esophageal hiatus into the thoracic cavity. Imaging revealed multiple pulmonary nodules without hepatic or lymph nodal metastases. Immunohistochemical analysis showed positivity for KIT and DOG1, and targeted sequencing identified a pathogenic <em>SDHB R46Q</em> variant. Surgical resection was deemed infeasible due to tumor size and location, and the patient received sequential systemic therapies including imatinib, sunitinib, regorafenib, and pimitespib. However, both primary lesion and pulmonary metastases demonstrated rapid progression, and the patient died within six months of treatment initiation. Succinate dehydrogenase (SDH)-deficient GISTs often involve hepatic and lymph node metastases but generally follow an indolent clinical course. However, this case demonstrated exclusive pulmonary metastases and rapid progression. The atypical metastatic pattern and aggressive course suggest biological heterogeneity within SDH-deficient GISTs and underscore importance of early molecular profiling and close clinical monitoring.</div></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":"19 ","pages":"Article 100388"},"PeriodicalIF":0.2,"publicationDate":"2025-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144858207","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-08-06DOI: 10.1016/j.cpccr.2025.100385
Monserrat Martínez Zamorano , Elizabeth Flores Solares , Tatiana Andrea Prado Salcedo , Karen Sofía Aguilera de Alba , María de Lourdes Sanchez Martínez
Introduction
Acral melanoma is a clinical subtype of melanoma that occurs on surfaces that do not develop hair, frequently metastasizes, and presents significant recurrence. Intestinal metastasis occurs in 0.3 % of cases and may exceptionally manifest as intussusception.
Presentation of case
A young adult man diagnosed with clinical stage IV acral melanoma came to the emergency room with abdominal pain, nausea, and hematemesis. An abdominal tomography was performed with data of intestinal intussusception with subsequent emergency laparotomy showing ileo-ileal invagination secondary to a hyperpigmented tumor lesion.
Discussion
Acral melanoma rarely develops intestinal metastases and it is even rarer to cause intussusception compared to other types of melanoma. Imaging studies are useful for diagnosis and emergency laparotomy is the procedure of choice. Surgical findings should be confirmed by histopathological study and individualized treatment should be offered.
Conclusion
Intestinal intussusception is a rare surgical emergency in adults; malignant etiology should be suspected from the patient's clinical history.
{"title":"Intestinal intussusception as a metastatic presentation of Acral Melanoma – Case report","authors":"Monserrat Martínez Zamorano , Elizabeth Flores Solares , Tatiana Andrea Prado Salcedo , Karen Sofía Aguilera de Alba , María de Lourdes Sanchez Martínez","doi":"10.1016/j.cpccr.2025.100385","DOIUrl":"10.1016/j.cpccr.2025.100385","url":null,"abstract":"<div><h3>Introduction</h3><div>Acral melanoma is a clinical subtype of melanoma that occurs on surfaces that do not develop hair, frequently metastasizes, and presents significant recurrence. Intestinal metastasis occurs in 0.3 % of cases and may exceptionally manifest as intussusception.</div></div><div><h3>Presentation of case</h3><div>A young adult man diagnosed with clinical stage IV acral melanoma came to the emergency room with abdominal pain, nausea, and hematemesis. An abdominal tomography was performed with data of intestinal intussusception with subsequent emergency laparotomy showing ileo-ileal invagination secondary to a hyperpigmented tumor lesion.</div></div><div><h3>Discussion</h3><div>Acral melanoma rarely develops intestinal metastases and it is even rarer to cause intussusception compared to other types of melanoma. Imaging studies are useful for diagnosis and emergency laparotomy is the procedure of choice. Surgical findings should be confirmed by histopathological study and individualized treatment should be offered.</div></div><div><h3>Conclusion</h3><div>Intestinal intussusception is a rare surgical emergency in adults; malignant etiology should be suspected from the patient's clinical history.</div></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":"19 ","pages":"Article 100385"},"PeriodicalIF":0.2,"publicationDate":"2025-08-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144831269","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
We present the case of a 67-year-old male with stage IV lung adenocarcinoma who developed pemetrexed-induced lipodermatosclerosis (LDS) and a flare of polymyalgia rheumatica (PMR) during chemotherapy treatment. Initially misdiagnosed as cellulitis, the patient experienced progressive skin toxicity that was ultimately recognized as LDS, associated with pemetrexed. The management of PMR flares and LDS was complex, requiring steroid therapy adjustments and the introduction of pentoxifylline. This case highlights the need for awareness of chemotherapy-induced skin toxicity and the challenges of managing underlying autoimmune conditions in cancer treatment.
{"title":"Pemetrexed-induced lipodermatosclerosis: clinical course and management of a rare cutaneous toxicity","authors":"Navkirat Kahlon , Shirisha Vallepu , Anusha Manje Gowda , Sujatha Baddam","doi":"10.1016/j.cpccr.2025.100386","DOIUrl":"10.1016/j.cpccr.2025.100386","url":null,"abstract":"<div><div>We present the case of a 67-year-old male with stage IV lung adenocarcinoma who developed pemetrexed-induced lipodermatosclerosis (LDS) and a flare of polymyalgia rheumatica (PMR) during chemotherapy treatment. Initially misdiagnosed as cellulitis, the patient experienced progressive skin toxicity that was ultimately recognized as LDS, associated with pemetrexed. The management of PMR flares and LDS was complex, requiring steroid therapy adjustments and the introduction of pentoxifylline. This case highlights the need for awareness of chemotherapy-induced skin toxicity and the challenges of managing underlying autoimmune conditions in cancer treatment.</div></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":"19 ","pages":"Article 100386"},"PeriodicalIF":0.2,"publicationDate":"2025-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144840993","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号